Patents by Inventor Xiao-kun Zhang
Xiao-kun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10087156Abstract: Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenviroment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.Type: GrantFiled: February 16, 2017Date of Patent: October 2, 2018Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, XIAMEN UNIVERSITYInventors: Xiao-kun Zhang, Ying Su, Hu Zhou, Wen Liu, Pei-Qiang Huang
-
Publication number: 20170313668Abstract: Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenviroment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.Type: ApplicationFiled: February 16, 2017Publication date: November 2, 2017Inventors: Xiao-kun ZHANG, Ying SU, Hu ZHOU, Wen LIU, Pei-Qiang HUANG
-
Patent number: 9611235Abstract: Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenvironment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.Type: GrantFiled: May 6, 2011Date of Patent: April 4, 2017Assignees: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, XIAMEN UNIVERSITYInventors: Xiao-kun Zhang, Ying Su, Hu Zhou, Wen Liu, Pei-Qiang Huang
-
Publication number: 20160340324Abstract: Embodiments provided herein relate to methods and compositions for treating cancer. Some embodiments relate to certain compounds having activity against retinoid X receptor-alpha (RXR?). Some embodiments included designing or identifying a compound that binds to human RXRa protein, such as the ligand binding domain (LBD) of human RXRa protein.Type: ApplicationFiled: December 22, 2014Publication date: November 24, 2016Inventors: Ying SU, Xiao-kun ZHANG
-
Publication number: 20150266842Abstract: Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenvironment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.Type: ApplicationFiled: May 6, 2011Publication date: September 24, 2015Inventors: Xiao-kun Zhang, Ying Su, Hu Zhou, Wen Liu, Pei-Qiang Huang
-
Publication number: 20130157260Abstract: An assay for identifying compounds that affect conversion of Bcl-2 family protein from an antiapoptotic to a proapoptotic form or inhibit activity of Bcl-2 family protein is described.Type: ApplicationFiled: December 2, 2010Publication date: June 20, 2013Applicant: Sanford-Burnham Medical Research InstituteInventors: Arnold Satterthwait, Xiao-kun Zhang, Xiuwen Zhu, Siva Kolluri, John C. Reed
-
Patent number: 8273705Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.Type: GrantFiled: February 2, 2009Date of Patent: September 25, 2012Assignee: The Burnham InstituteInventors: John C. Reed, Xiao-kun Zhang, Bin Guo, Bingzhen Lin, Siva Kumar Kolluri
-
Patent number: 8105798Abstract: This invention relates to methods for identifying agents useful for treatment of diseases and pathological conditions affected by Retinoid X Receptor apoptosis. The invention also relates to methods for treating diseases and pathological conditions affected by RXR apoptosis. The invention includes compositions that are useful in the study and treatment of diseases and pathological conditions affected by RXR apoptosis.Type: GrantFiled: August 13, 2004Date of Patent: January 31, 2012Assignee: The Burnham InstituteInventors: Xiao-kun Zhang, Xihua Cao, Wen Liu
-
Publication number: 20100292145Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing or preventing apoptosis are described, together with methods for identifying molecules that induce or prevent apoptosis through interaction with Bcl-2-family members. Methods for treatment of proliferative diseases and neurodegenerative diseases using the modulators of Bcl-2 and related family members are also disclosed.Type: ApplicationFiled: June 15, 2010Publication date: November 18, 2010Applicant: Sanford-Burnham Medical Research InstituteInventors: Arnold Satterthwait, Xiao-kun Zhang, Xiuwen Zhu, Siva Kolluri
-
Patent number: 7745574Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing or preventing apoptosis are described, together with methods for identifying molecules that induce or prevent apoptosis through interaction with Bcl-2-family members. Methods for treatment of proliferative diseases and neurodegenerative diseases using the modulators of Bcl-2 and related family members are also disclosed.Type: GrantFiled: May 11, 2006Date of Patent: June 29, 2010Assignee: The Burnham InstituteInventors: Arnold Satterthwait, Xiao-kun Zhang, Xiuwen Zhu, Siva Kolluri
-
Publication number: 20090215984Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.Type: ApplicationFiled: February 2, 2009Publication date: August 27, 2009Applicant: The Burnham InstituteInventors: John C. Reed, Xiao-kun Zhang, Bin Guo, Bingzhen Lin, Siva Kumar Kolluri
-
Patent number: 7491700Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.Type: GrantFiled: January 4, 2007Date of Patent: February 17, 2009Assignee: The Burnham InstituteInventors: John C. Reed, Xiao-kun Zhang, Bin Guo, Bingzhen Lin, Siva Kumar Kolluri
-
Publication number: 20070117753Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.Type: ApplicationFiled: January 4, 2007Publication date: May 24, 2007Applicant: The Burnham InstituteInventors: John Reed, Xiao-kun Zhang, Bin Guo, Bingzhen Lin, Siva Kolluri
-
Publication number: 20070054863Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing or preventing apoptosis are described, together with methods for identifying molecules that induce or prevent apoptosis through interaction with Bcl-2-family members. Methods for treatment of proliferative diseases and neurodegenerative diseases using the modulators of Bcl-2 and related family members are also disclosed.Type: ApplicationFiled: May 11, 2006Publication date: March 8, 2007Inventors: Arnold Satterthwait, Xiao-kun Zhang, Xiuwen Zhu, Siva Kolluri
-
Patent number: 7176277Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.Type: GrantFiled: October 7, 2005Date of Patent: February 13, 2007Assignee: The Burnham InstituteInventors: John C. Reed, Xiao-kun Zhang, Bin Guo, Bingzhen Lin, Siva Kumar Kolluri
-
Publication number: 20060193864Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.Type: ApplicationFiled: October 7, 2005Publication date: August 31, 2006Inventors: John Reed, Xiao-kun Zhang, Bin Guo, Bingzhen Lin, Siva Kolluri
-
Patent number: 7098310Abstract: This invention provides a purified heterodimer comprising an RXR and a hormone receptor. The invention also provides a method of screening ligands for their effect on the activity of an RXR-containing hormone receptor heterodimer comprising combining the heterodimer with the ligand and determining the effect on activity. Also provided is a method of amplifying the activity of a hormone receptor comprising forming a heterodimer with another hormone receptor.Type: GrantFiled: December 24, 1991Date of Patent: August 29, 2006Assignee: Ligand PharmaceuticalsInventors: Magnus Pfahl, Xiao-kun Zhang
-
Patent number: 7053071Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.Type: GrantFiled: December 2, 2002Date of Patent: May 30, 2006Assignee: The Burnham InstituteInventors: Marcia Dawson, Joseph A. Fontana, Xiao-kun Zhang, Mark Leid, Ling Jong, Peter D. Hobbs
-
Patent number: 7026125Abstract: This invention provides a purified heterodimer comprising an RXR and a hormone receptor. The invention also provides a method of screening ligands for their effect on the activity of an RXR-containing hormone receptor heterodimer comprising combining the heterodimer with the ligand and determining the effect on activity. Also provided is a method of amplifying the activity of a hormone receptor comprising forming a heterodimer with another hormone receptor.Type: GrantFiled: January 15, 1999Date of Patent: April 11, 2006Assignee: Ligand PharmaceuticalsInventors: Magnus Pfahl, Xiao-kun Zhang
-
Patent number: RE42700Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis of apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.Type: GrantFiled: July 25, 2008Date of Patent: September 13, 2011Assignees: Sanford-Burnham Medical Research Institute, Oregon State University, SRI International, Molecular Medicine Research Institute, Department of Veterans Affairs, Wayne State UniversityInventors: Marcia Dawson, Joseph A. Fontana, Xiao-Kun Zhang, Mark Leid, Ling Jong, Peter D. Hobbs